Cartesian Therapeutics (RNAC) Enterprise Value (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Enterprise Value for 11 consecutive years, with -$125.1 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 41.14% to -$125.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$125.1 million, a 41.14% increase, with the full-year FY2025 number at -$125.1 million, up 41.14% from a year prior.
- Enterprise Value was -$125.1 million for Q4 2025 at Cartesian Therapeutics, up from -$143.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$76.9 million in Q4 2023 to a low of -$219.2 million in Q3 2024.
- A 5-year average of -$136.6 million and a median of -$136.6 million in 2021 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 45.64% in 2023, then crashed 176.44% in 2024.
- Cartesian Therapeutics' Enterprise Value stood at -$128.1 million in 2021, then decreased by 5.11% to -$134.6 million in 2022, then skyrocketed by 42.86% to -$76.9 million in 2023, then crashed by 176.44% to -$212.6 million in 2024, then soared by 41.14% to -$125.1 million in 2025.
- Per Business Quant, the three most recent readings for RNAC's Enterprise Value are -$125.1 million (Q4 2025), -$143.4 million (Q3 2025), and -$160.3 million (Q2 2025).